Watch TDAC. Know when insiders buy.
One email the day a filing lands. Free.
TDAC
Translational Development Acquisition Corp.
10.85
−0.02 −0.18%
USD · close Sep 28
A free account adds a watchlist, alerts when insiders, Congress or short sellers move on your tickers, and a morning brief. Sign up
Work order
100
PASS · shorts 100
Insiders, 90 days
0
no open-market filings in 90 days
Congress, 90 days
0 / 0
no disclosures naming it
Big money
0 / 15
none of the tracked funds disclose it
Calls on record
0
nobody we score has called it yet
MKT CAP —P/E —DIV YIELD —FCF YIELD —REV TTM —NET INCOME $5.5M +82.3%NET CASH —52W 10.34 – 10.90SEC XBRL · TTM TO Invalid Date
Financials
By quarter
| Period | Revenue | YoY | Gross margin | Operating income | Net income | YoY | EPS | Op. cash flow | Capex | Free cash flow | Filed |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Q2 2026 · Jun 30 | — | — | — | −$661K | $947K | −41.7% | — | −$339K | — | — | Aug 14 |
| Q1 2026 · Mar 31 | — | — | — | −$281K | $1.3M | −10.1% | — | −$305K | — | — | Aug 14 |
| Q4 2025 · Dec 31derived | — | — | — | −$162K | $1.6M | — | — | −$117K | — | — | Mar 30 |
| Q3 2025 · Sep 30 | — | — | — | −$214K | $1.7M | — | — | −$88K | — | — | Nov 14 |
| Q2 2025 · Jun 30 | — | — | — | −$221K | $1.6M | — | — | −$171K | — | — | Aug 14 |
| Q1 2025 · Mar 31 | — | — | — | −$347K | $1.5M | — | — | −$232K | — | — | Aug 14 |
| Q4 2024 · Dec 31derived | — | — | — | −$133K | −$8K | — | — | −$811K | — | — | Mar 30 |
| Q3 2024 · Sep 30 | — | — | — | −$61K | −$61K | — | — | — | — | — | Nov 14 |
| Q2 2024 · Jun 30 | — | — | — | −$2K | −$2K | — | — | — | — | — | Nov 14 |
| Q1 2024 · Mar 31 | — | — | — | $0 | $0 | — | — | — | — | — | Nov 14 |
By fiscal year
| Year | Revenue | Gross margin | Operating income | Net income | Net margin | EPS | Op. cash flow | Capex | Free cash flow | Buybacks | Dividends paid |
|---|---|---|---|---|---|---|---|---|---|---|---|
| FY2025 · to Dec 31 | — | — | −$945K | $6.4M | — | — | −$608K | — | — | — | — |
| FY2024 · to Dec 31 | — | — | −$196K | −$71K | — | — | −$851K | — | — | — | — |
| FY2023 · to Dec 31 | — | — | −$486K | −$486K | — | — | −$204 | — | — | — | — |
Every number comes from Translational Development Acquisition Corp.'s own XBRL-tagged filings with the SEC, not a data vendor. Quarters marked derived are the fiscal year minus the three reported quarters, the same way every data provider computes Q4. Restated figures replace originals as later filings arrive.